)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Cadrenal Therapeutics
Cadrenal Therapeutics (CVKD) investor relations material
Cadrenal Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary3 Aug, 2026
Executive summary
Annual meeting scheduled for September 24, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by September 23, 2026.
Voting can be completed online, by phone, or by requesting paper/email materials.
Voting matters and shareholder proposals
Election of Quang X. Pham as director is up for shareholder vote.
Ratification of WithumSmith + Brown, PC as independent auditor for fiscal year ending December 31, 2026.
Proposal to amend the 2022 Successor Equity Incentive Plan to increase available shares for awards to 1,000,000.
Approval sought for issuance of up to 960,000 shares upon exercise of Series C-1 warrants from a July 2026 private placement.
Proposal to allow adjournment of the meeting if more time is needed for proxy solicitation on key proposals.
Board of directors and corporate governance
Board recommends approval of all proposals presented for the 2026 annual meeting.
Only one director nominee, Quang X. Pham, is listed for election.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cadrenal Therapeutics
- Stockholders will vote on director election, auditor ratification, equity plan, and warrant issuance.CVKD
Proxy filing3 Aug 2026 - Stockholders will vote on director election, auditor ratification, equity plan, and warrant issuance.CVKDProxy filing23 Jul 2026
- Registering 2.94M shares for resale from PIPE warrants, with high dilution and capital risk.CVKDRegistration filing13 Jul 2026
- CAD-1005 offers a novel, upstream approach to HIT, aiming to improve outcomes and reduce costs.CVKDLytham Partners Spring 2026 Investor Conference28 May 2026
- First-in-class 12-LOX inhibitor CAD-1005 targets HIT, aiming for $1B+ market with Phase 3 in 2027.CVKDInvestor presentation7 May 2026
- Net loss narrowed and cash runway extended by $2.5M financing, enabling Phase 3 trial advancement.CVKDQ1 20267 May 2026
- Biopharma firm registers 1.18M shares for resale; proceeds from warrant exercises fund operations.CVKDRegistration filing21 Apr 2026
- Phase 2 CAD-1005 data show >25% reduction in HIT thrombotic events; Phase 3 planning underway.CVKDQ4 202531 Mar 2026
- CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data.CVKDLife Sciences Virtual Investor Forum12 Mar 2026
Next Cadrenal Therapeutics earnings date
Q2 202614 Aug, 2026
Cadrenal Therapeutics
Next Cadrenal Therapeutics earnings date
Q2 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage